CraniUS Therapeutics Achieves FDA Clearance for Innovative Cranial Implant Solution
On September 9, 2026, CraniUS Therapeutics announced a pivotal advancement in neurotechnology with the FDA's granting of 510(k) clearance for the CraniUS Plate, a groundbreaking patient-specific cranial implant. This device, designed for the reconstruction of cranial defects, represents the company's first commercially available product, paving the way for further innovations in neurosurgery.
The CraniUS Plate, referred to as NeuroPASS 1, is more than just a product; it symbolizes a significant leap from the development phase to the practical application that neurosurgeons can leverage to improve patient outcomes. As noted by Michael Maglin, the Chief Executive Officer of CraniUS Therapeutics, this achievement is a testament to the hard work and dedication of the team, marking an essential turning point for the company.
Recognized as a Class II preformed alterable cranioplasty plate regulated under 21 CFR 882.5320 (product code GWO), the CraniUS Plate was evaluated by the FDA’s Center for Devices and Radiological Health. The substantial equivalence determination was issued on July 29, 2026, allowing for the marketing of this innovative device in the U.S. market.
What sets the CraniUS Plate apart is its patient-specific design. Each implant is tailored to match the unique anatomy of individual patients, offering neurosurgeons and craniofacial surgeons a custom solution for reconstructing cranial defects arising from various conditions, including traumatic injuries, tumor removals, and decompressive craniectomies.
Dr. Chad Gordon, Founder and Chief Medical Officer of CraniUS Therapeutics, emphasizes the product's innovative approach. He suggests that cranial reconstruction has historically been treated merely as a structural challenge; however, the area beneath the plate harbors incredible potential. The company envisions that a cleared, individualized plate could profoundly change the ways cranial implants support patient healing and treatment.
The NeuroPASS platform, with the CraniUS Plate as its first offering, aims to expand the boundaries of cranial implant technology. It is being developed to include features such as durable access to the brain, integrated sensing, diagnostics, and long-term therapeutic drug delivery mechanisms, which would allow healthcare providers to address a range of neurological conditions effectively. These objectives are part of ongoing investigational programs that are yet to receive regulatory approval.
Mark Wladkowski, Chief Operating Officer and CTO of CraniUS Therapeutics, highlighted the importance of the NeuroPASS 1 as a foundational component of a larger vision. This platform is designed to adapt and grow; as new functionalities are developed, they can seamlessly expand upon the initial implant structure.
Presently, the CraniUS Plate is exclusively cleared for cranial defect repair. Still, the potential application of the NeuroPASS platform to facilitate critical neurological interventions continues to inspire both the company’s strategy and the broader medical community.
Founded in 2021, CraniUS Therapeutics is a forward-thinking neurotechnology firm headquartered in Baltimore. The company's mission encompasses not only providing pioneering products like the CraniUS Plate but also advancing neurotechnology to form a comprehensive approach to treat severe neurological ailments across diverse patient populations. By collaborating with clinical and research partners worldwide, CraniUS is poised to make substantial contributions to the field of neurosurgery.
It is crucial to keep in mind that while the developments surrounding the NeuroPASS platform are promising, they remain in the investigational stage and have not yet been authorized by the FDA. Forward-looking statements made by company officials regarding these future capabilities underscore the innovative spirit driving CraniUS Therapeutics' efforts in this challenging arena. As the field of neurosurgery evolves, the introduction of patient-specific solutions like the CraniUS Plate marks a promising chapter in enhancing patient care and surgical outcomes.
The CraniUS Plate, referred to as NeuroPASS 1, is more than just a product; it symbolizes a significant leap from the development phase to the practical application that neurosurgeons can leverage to improve patient outcomes. As noted by Michael Maglin, the Chief Executive Officer of CraniUS Therapeutics, this achievement is a testament to the hard work and dedication of the team, marking an essential turning point for the company.
Recognized as a Class II preformed alterable cranioplasty plate regulated under 21 CFR 882.5320 (product code GWO), the CraniUS Plate was evaluated by the FDA’s Center for Devices and Radiological Health. The substantial equivalence determination was issued on July 29, 2026, allowing for the marketing of this innovative device in the U.S. market.
What sets the CraniUS Plate apart is its patient-specific design. Each implant is tailored to match the unique anatomy of individual patients, offering neurosurgeons and craniofacial surgeons a custom solution for reconstructing cranial defects arising from various conditions, including traumatic injuries, tumor removals, and decompressive craniectomies.
Dr. Chad Gordon, Founder and Chief Medical Officer of CraniUS Therapeutics, emphasizes the product's innovative approach. He suggests that cranial reconstruction has historically been treated merely as a structural challenge; however, the area beneath the plate harbors incredible potential. The company envisions that a cleared, individualized plate could profoundly change the ways cranial implants support patient healing and treatment.
The NeuroPASS platform, with the CraniUS Plate as its first offering, aims to expand the boundaries of cranial implant technology. It is being developed to include features such as durable access to the brain, integrated sensing, diagnostics, and long-term therapeutic drug delivery mechanisms, which would allow healthcare providers to address a range of neurological conditions effectively. These objectives are part of ongoing investigational programs that are yet to receive regulatory approval.
Mark Wladkowski, Chief Operating Officer and CTO of CraniUS Therapeutics, highlighted the importance of the NeuroPASS 1 as a foundational component of a larger vision. This platform is designed to adapt and grow; as new functionalities are developed, they can seamlessly expand upon the initial implant structure.
Presently, the CraniUS Plate is exclusively cleared for cranial defect repair. Still, the potential application of the NeuroPASS platform to facilitate critical neurological interventions continues to inspire both the company’s strategy and the broader medical community.
Founded in 2021, CraniUS Therapeutics is a forward-thinking neurotechnology firm headquartered in Baltimore. The company's mission encompasses not only providing pioneering products like the CraniUS Plate but also advancing neurotechnology to form a comprehensive approach to treat severe neurological ailments across diverse patient populations. By collaborating with clinical and research partners worldwide, CraniUS is poised to make substantial contributions to the field of neurosurgery.
It is crucial to keep in mind that while the developments surrounding the NeuroPASS platform are promising, they remain in the investigational stage and have not yet been authorized by the FDA. Forward-looking statements made by company officials regarding these future capabilities underscore the innovative spirit driving CraniUS Therapeutics' efforts in this challenging arena. As the field of neurosurgery evolves, the introduction of patient-specific solutions like the CraniUS Plate marks a promising chapter in enhancing patient care and surgical outcomes.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.